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Levels of CD4+ CD25+ T regulatory cells in bronchial mucosa 
and peripheral blood of chronic obstructive pulmonary disease 
indicate involvement of autoimmunity mechanisms
Abstract
Introduction: Many theories have been proposed to explain pathogenesis of COPD; however, remains unclear why the majority 
of smokers (~80%) do not develop COPD, or only develop a mild disease. To explore if COPD has an autoimmune component, the 
role of T regulatory lymphocytes (Tregs) in the lung tissue of COPD patients is of crucial importance. 
Material and methods: Bronchial tissue biopsy samples were prospectively collected from 64 patients (39 COPD and 25 con-
trols — 15 smokers and 10 non-smokers). The patients with COPD were subdivided into mild/moderate (GOLD stage I−II) and 
severe/very severe (GOLD stage III−IV) groups. Digital image analysis was performed to estimate densities of CD4+ CD25+ 
cell infiltrates in double immunohistochemistry slides of the biopsy samples. Blood samples were collected from 42 patients (23 
COPD and 19 controls) and tested for CD3+ CD4+ CD25+ bright lymphocytes by flow cytometry.
Results: The number of intraepithelial CD4+ CD25+ lymphocytes mm-2 epithelium was significantly lower in the severe/very 
severe COPD (GOLD III-IV) group as well as in the control non-smokers (NS) group (p < 0,0001). Likewise, the absolute number 
of Treg (CD3+ CD4+ CD25+ bright) cells in the peripheral blood samples was significantly different between the four groups (p = 
0.032). The lowest quantity of Treg cells was detected in the severe/very severe COPD and healthy non-smokers groups. 
Conclusion: Our findings suggest that severe COPD is associated with lower levels of Tregs in the blood and bronchial mucosa, 
while higher Tregs levels in the smokers without COPD indicate potential protective effect of Tregs against developing COPD.
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is characterized by poorly reversible 
airflow limitation and progressive airway inflam-
mation [1]. The most common cause of COPD 
is cigarette smoking. Many theories have been 
proposed to explain the mechanisms and deve-
lopment of the disease, however, relatively little 
attention is being paid to why and how the ma-
jority of smokers (~80%) do not develop COPD, 
or only develop a mild disease [2]. 
What are the mechanisms that allow the 
majority of smokers to evade COPD? Autoim-
munity has been suspected to play a role in the 
pathogenesis of COPD, but the antigenic stimu-
lation responsible for lymphocyte activation is 
not established. Possibilities include viruses or 
bacteria residing in the airways, or smoking al-
tering the presentation of self-antigens including 
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elastin [3]. A key clinical observation supporting 
this hypothesis is that airway inflammation is 
progressive in many patients, despite smoking 
cessation [4, 5]. The development of an adaptive 
immune response to a self-antigen, along with the 
eventual development of autoimmunity, would 
depend on the level of tolerance to the antigen: 
when tolerance is high, no adaptive inflammation 
would result; when there is no tolerance, a full 
adaptive immune reaction and autoimmunity 
would develop [2]. 
The autoimmunity component of COPD can 
be evaluated by investigating the function of re-
gulatory T lymphocytes (Tregs) in the lung tissue 
[6]. Treg lymphocytes are a subset of CD4 positive 
lymphocytes co-expressing CD25. They suppress 
autoreactive lymphocytes by a variety of mecha-
nisms, including cell-to-cell contact and secretion 
of immunomodulatory cytokines [7]. It has been 
reported that smokers have increased numbers of 
Treg cells in bronchoalveolar lavage fluid [8, 9] 
compared to non-smokers. One of these studies 
also showed decreased Treg numbers in COPD 
patients compared to smokers with normal lung 
function, suggesting decreased T regulatory func-
tion in COPD. The presence of Tregs in the lungs 
of COPD patients has been studied by a number 
of investigators [6, 8, 10−12], but data remain 
controversial. The contrasting findings regarding 
Treg cell numbers in different studies may be 
partly explained by methodology aspects such as 
the site of sampling and the laboratory methods 
used to identify Tregs. Another important factor 
is the heterogeneity of COPD [6].
To our knowledge, quantities of Treg cells 
in large airways in conjunction with peripheral 
blood in various stages of COPD patients have not 
been previously studied. The aim of our study 
was to evaluate CD4+ CD25+ Treg cells numbers 
in endobronchial biopsy samples and peripheral 
blood in all stages COPD patients and compare 
results with the control group of non-smokers and 
smokers without COPD.
Materials 
Patients and control subjects
The study cohort consisted of 64 persons. 
All subjects were Caucasians. Thirty-nine COPD 
patients at the age of 35−77 (mean age 64) were 
recruited (Table 1). All patients had a post-bron-
chodilator FEV1/FVC < 70% and <  LLN, as well 
as smoking history of more than 10 pack-years. 
According to the severity of the disease, the pa-
tients with COPD were divided into two following 
groups — mild/moderate (GOLD stage I−II) group 
and severe/very severe (GOLD stage III−IV) group, 
respectively. None had clinical or radiological 
features of any other lung disease than COPD. 
Smokers with normal lung function (n = 15) and 
non-smokers (n = 10) served as controls. All sub-
jects in the control group were volunteers and did 
not have any lung disease, including lung cancer. 
The patients with bronchial biopsy examination 
were the same from which peripheral blood was 
analysed.
Bronchial tissue biopsy samples were pro-
spectively collected from 64 patients and investi-
gated at the National Center of Pathology. Blood 
samples were collected from 42 participants: 
23 COPD (12 of mild/moderate, 11 of severe/very 
severe group and 19 controls [11 smokers and 
8 non-smokers]). Informed consent was obtained 
and documented in writing before the study en-
try. The research was approved by the Regional 
Bioethics Committee.
Pulmonary function test
All patients and controls underwent spirome-
try. Pre- and post-bronchodilator spirometry was 
performed according to the American Thoracic 
Society (ATS)/European Respiratory Society (ERS) 
guidelines. PFT parameters, including FEV1, FEV1/ 
/FVC ratio and FVC were measured using Vmax 
Encore (Viasys ®Healthcare, US) equipment. The 
subsequent blood specimen was obtained and 
bronchoscopy was performed.
Bronchoscopy and bronchial biopsies
Bronchoscopy procedures were carried out 
using fiber bronchoscopes manufactured by 
Olympus® and Pentax® (Japan). The procedure 
was performed when the patient was sitting. The 
subjects received 1.0 ml of atropine sulphate 0.1% 
subcutaneously for premedication. Anaesthesia 
of the nose and throat was performed using Lido-
caine 10% spray solution administered into both 
nostrils and the throat. The trachea and bronchi 
were anaesthetized using 20 ml of Lidocaine 2% 
solution. Biopsy specimens were taken by use 
of pulmonary biopsy forceps. From each subject 
six endobronchial mucosal biopsies were taken 
from the subsegmental carina of the inferior lobe 
of the right lung.
Processing and staining of bronchial 
biopsies
The tissue samples were fixed in 10% buffe-
red formalin and embedded in paraffin. Paraffin 
sections were cut 2 μm thick. Double IHC was 
Virginija Sileikiene et al., T regulatory cells in COPD
161www.journals.viamedica.pl
Table 1. Demographic and lung function characteristics of individuals with and without COPD
COPD group Control group
Mild/moderate
(GOLD I−II)
n = 19
Severe/very severe
(GOLD III−IV)
n = 20
Smokers
n = 15
Non-smokers
n = 10
Gender, male/female 17/2 20/0 10/5 5/5
Age, years 60 ± 16 67 ± 10 47 ± 14 50 ± 9
Smoking history,
pack/years*
29 ± 18 40 ± 10 25 ± 12 0
FEV1/FVC 52.47 ± 9.03# 39.63 ± 7.13# 80.18 ± 5.91 77.50 ± 7.61
FEV1% pred 67.58 ± 11.60# 40.53 ± 5.94# 105.45 ± 9.58## 105.83 ± 23.37##
FVC% pred 103.11 ± 18.79# 81.68 ± 15.86# 109.91 ± 10.25 112.17 ± 23.46
Data are presented as mean ± standard deviation (SD). FVC — forced vital capacity; pred, predicted; FEV1 — forced expiratory volume in one second. *One-way Anova 
not indicated significant difference of lung function parameters in both COPD groups and control group of smokers. #Statistically significant differences were indicated 
between GOLD I−II, GOLD III−IV, smokers and non-smokers groups (p < 0.0001) using Kruskal Wallis Test. ##Statistically significant differences in FEV1 were not 
indicated between smokers and non-smokers groups using ANOVA post hoc test
performed applying rabbit monoclonal antibodies 
against CD4 (clone: SP35, Cell Marque) and human 
interleukin-2 receptor (CD25, clone: 4C9, Leica) 
with brown (diaminobenzidine) and red (Nuclear 
fast red) chromogens, respectively (Figure 1). Epi-
tope retrieval was performed using Target buffer 
solution pH 9.0 at 97°C for 20 min and Cell Con-
ditioning solution (pH 8.5) at 95°C for 64 min. The 
sections were then incubated with CD4 (1:25) anti-
body at 37°C for 32 min and CD25 (1:100) antibody 
at room temperature for 30 min, using EnVision 
FLEX+ Mouse, High pH visualization kit, based 
on peroxidase (HRP) with DAB+ as chromogen 
and ultraView Universal alkaline phosphatase (AP) 
using Permanent Red as chromogen. DAKO Auto-
stainer Link machine (DAKO, Agilent technologies, 
Santa Clara, CA) and Benchmark Ultra automated 
staining system (Ventana Medical Systems, Tucson, 
Arizona, USA) was used for the procedure. Finally, 
the sections were counterstained with Mayer’s he-
matoxylin and mounted. Tissue sections of CD4 
and CD25 positive bronchus tissue were used as 
positive tissue controls, while negative reagent 
controls were performed by omitting application 
of the primary antibodies. 
Quantification of staining in mucosal 
biopsy specimens
Digital images were captured using the Aperio 
ScanScope XT Slide Scanner (Aperio Technologies, 
Vista, CA, USA) under 20× objective magnifica-
tion. Digital image analysis (DIA) was performed 
with StrataQuest v.205 (TissueGnostics GmbH). 
The tissue sections were divided into three zones: 
the epithelium, subepithelial stroma and rema-
ining stroma/other tissue. The epithelial layer was 
manually annotated; the subepithelial stroma was 
automatically separated from the remaining stroma 
as a ribbon of 1 mm in thickness underneath the 
epithelium by appropriate StrataQuest algorithm 
setup (Figure 2). Densities of CD4+ CD25+ lym-
phocytes infiltrate (numbers of cells per square 
mm) were calculated in the tissue compartments.
Peripheral blood. Immunostaining and 
flow cytometry 
For lymphocyte subpopulation analysis, 
peripheral blood samples were incubated with 
monoclonal antibodies for 15 minutes at the 
Figure 1. Representative photomicrograph showing bronchial epithe-
lium of patients in the COPD group: double immunohistochemistry for 
CD4 (brown) and CD25 (red)
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Figure 2. Segmentation of the epithelium (yellow), subepithelial stroma (grey) and the remaining stroma/other tissue (red) in the StrataQuest image 
analysis platform
CD3+ lymphocytes
CD3+ CD4+ CD25+ bright
room temperature in the dark. Following the in-
cubation, 2 mL of red cell lysing buffer (BD FACS 
lysis solution, BD Biosciences San Jose, CA, USA) 
was added, cells were incubated for 10 minutes at 
room temperature in the dark. After centrifugation 
at 300 g for 7 minutes at room temperature, the 
supernatant was discarded and 2 ml of phosphate 
buffered saline (PBS) was added to the pellet. 
Re-suspended cells were washed by centrifuga-
tion at 300 g for 7 minutes at room temperature. 
After fixation in 300 μl of 0.5% paraformaldehyde, 
prepared samples were analyzed on FACSCalibur 
flow cytometer (BD Biosciences) using CellQu-
estPro analysis software. Antibodies used for 
lymphocytes characterization were: Peridinin 
Chlorophyll Protein Complex (Per CP) conjugated 
anti-CD3 monoclonal antibodies, Phycoerythrin 
(PE) conjugated anti-CD25 monoclonal antibodies 
and Fluorescein isothiocyanate (FITC) conjugated 
anti-CD4 monoclonal antibodies (all monoclonal 
antibodies BD Biosciences, San Jose, CA, USA). 
Lymphocytes were gated on a  forward scatter 
versus CD3+ Per CP (Figure 3). CD25 expression 
on CD4 + T cells was categorized into CD25 (dim) 
and CD25 (bright) subpopulations; the absolute 
number CD3+ CD4+ CD25+ bright was analyzed 
as Tregs.
Statistical analysis
Statistical analysis was performed by using 
SPSS version 22.0 (SPSS Inc., Chicago Ill). Con-
tinuous data are given as mean ± SD. Kolmogo-
rov−Smirnov test was applied for assessing the 
normality of data. For normally distributed data, 
comparisons between groups were made using 
analysis of variance one-way ANOVA. If data was 
not normally distributed, Kruskal–Wallis test was 
used. Pearson r correlation coefficient was applied 
to evaluate the correlation. Statistical significance 
was defined at p < 0.05.
Figure 3. Flow cytometry analysis of CD25 expression on peripheral blood CD4+ T cells. A. Lymphocytes were gated on a forward scatter versus 
CD3+ Per CP; B. Dot plot of blood CD3+ CD4+ CD25+ lymphocytes: CD25 expression was categorized into CD25 (dim) and CD25 (bright) subpo-
pulations (CD3+ CD4+ CD25+ bright analyzed as Tregs)
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Results
Biopsy findings
There was no significant difference in analy-
zed epithelial length, expressed in mm, between 
the groups. The number of intraepithelial CD4+ 
CD25+ lymphocytes mm-2 epithelium was signi-
ficantly different between the groups (p < 0.0001; 
Kruskall–Wallis), Figure 4. However, there was 
no difference of subepithelial and stromal CD4+ 
CD25+ lymphocytes between the groups (p = 
0.062 and p = 0.117, respectively).
Peripheral blood findings
Similar to the biopsy results, the absolute 
number of Treg (CD3+ CD4+ CD25+ bright) cells 
in the peripheral blood samples was significan-
tly different between the four groups (p=0.032), 
Figure 5. 
However, there is no statistically significant 
difference between the groups in the absolute 
number and percent of all CD3+ CD4+ CD25+ 
lymphocytes (p = 0.076 and p = 0.056, respec-
tively).
The lowest quantity of Treg cells was detec-
ted in severe/very severe COPD and healthy non-
-smokers groups. Weak, but not statistically signi-
ficant correlation between blood and epithelial 
Tregs numbers was noted (r = 0.241, p = 0.124).
Discussion
Our study was driven by the question why 
COPD affects only a small proportion of smokers 
and if immune mechanisms play a  role in the 
Figure 4. The mean of intraepithelial Tregs mm-2 epithelium in bronchial 
biopsies in the study groups. The number of intraepithelial CD4+ 
CD25+ lymphocytes mm-2 epithelium was significantly lower in the 
severe/very severe COPD (GOLD III−IV) group as well as in the control 
non-smokers (NS) group (p < 0.0001). Data are presented as mean ± 
standard deviation (SD)
Figure 5. Comparison of the means of Tregs (CD3+ CD4+ CD25+bright) 
number in peripheral blood in groups. Tregs number is significantly 
lower in severe/very severe COPD (GOLD III−IV) and in the control non-
smokers (NS) group. Data are shown as median and interquartile range 
development of this disease. In the study, we 
demonstrate differences in intraepithelial and 
peripheral blood Treg cells in mild/moderate and 
severe/very severe stable COPD compared to smo-
kers with normal lung function and non-smokers. 
Our data indicate decreased Treg cells in bron-
chial epithelium in severe/very severe COPD as 
well as in the control non-smoker group, compa-
red to mild/moderate COPD and healthy smokers. 
This suggests that severe COPD is diagnosed in 
patients with lower levels of Tregs in the blood 
and respiratory tract, while higher Tregs levels 
in smokers without COPD indicate a potential 
Treg protective effect against developing COPD.
A  role of autoimmune-mediated inflam-
mation in COPD was first suspected by Saetta 
et al. [13] when histological studies of human 
lung tissue revealed a preponderance of CD8+ 
T cells in the small and large airway biopsies in 
ever-smokers with COPD. The intriguing clinical 
and pathological observations made over the past 
few years have led to a new concept: in suscep-
tible individuals, cigarette-smoke exposure may 
trigger long-lasting inflammatory memory T-cell 
responses that can persist beyond the immedia-
te period of exposure to cigarette smoke. Most 
importantly, the continuous recruitment of acti-
vated lung antigen presenting cells (APCs) could 
further ensure propagation of auto-inflammatory 
T-cell responses and the development of chronic 
progressive lung destruction [14]. 
It has been shown that Treg cells are impor-
tant in the control of autoimmunity. Domagala-
-Kulawik et al. [15] observed significantly lower 
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proportion of peripheral blood CD4+ CD25+ lym-
phocytes in mild/moderate COPD patients than 
in healthy controls. This finding drew attention 
to the fact that, comparing with healthy people, 
patients with COPD have less of these immune 
cells in the blood, consequently, a certain level 
of immune response has been altered in COPD 
patients. Unlike these authors, we have investi-
gated not only moderate, but also severe COPD 
patients and the control group was divided into 
two parts: smokers and non-smokers. The bre-
akdown of subjects into four groups allowed us 
to assess this chain of immune response in COPD 
in a more detailed way. We found that the number 
of Treg cells was significantly different between 
milder and more severe COPD patients as well 
as in control smokers and non-smokers groups. 
These findings give us a possibility to consider 
the involvement of immune mechanisms for the 
development of COPD. 
An interesting observation was published by 
Xiang-Nan Li and coworkers [16], who reported 
imbalances of Th17 and Treg cells and their re-
spective cytokines in COPD patients. The propor-
tion of proinflammatory Th17 cells in peripheral 
blood and in sputum was significantly higher in 
acute exacerbation of COPD than in stable COPD 
patients and the control group of smokers with 
normal lung function. Additionally, the propor-
tion of Treg cells was lower than in stable COPD 
but higher than in controls. Thus, COPD patients 
have shifts in the balance of Th17/Treg cells. In 
contrast to Th17 cells, Treg cells can be immuno-
suppressive, secreting the anti-inflammatory cyto-
kines such as interleukin (IL)-10 and transforming 
growth factor (TGF)-ß1 to strengthen immune 
tolerance and inhibit inflammatory responses.
 On the basis of the presence of B-cell lym-
phoid follicles in patients with advanced COPD 
and the detection of diverse autoantibodies in 
a subgroup of patients with COPD, COPD has 
been regarded as an autoimmune disease [18]. 
Plumb and coworkers [3] were first to study Tregs 
in pulmonary lymphoid follicles. It was revealed 
that there was an increased proportion of Treg 
cells within pulmonary lymphoid follicles of 
moderate severity COPD patients compared to 
smokers and non-smokers. However, in clusters 
and the subepithelia, there was no difference in 
the proportion of Treg cells between the groups. 
Although the number of Treg cells in COPD was 
elevated, in the opinion of the authors, T-regulato-
ry activity may be altered within COPD lymphoid 
follicles. However, the study included only mode-
rate COPD patients. This is important because the 
prevalence of lymphoid follicles increases sharply 
from 25% to 30% in severe and very severe COPD 
for unclear reasons [17]. The progression from 
moderate to severe COPD, which is associated 
with a sharp increase in the number of follicles, 
may arise from a failure of regulatory mechanisms 
to suppress autoimmunity.
Another study that showed the possible pro-
tective function of Treg in the lungs demonstrated 
that smokers with COPD and emphysema had 
significantly fewer Treg cells in the lungs and 
lower interleukin 10 concentrations from the 
whole lung than controls [10].
CD4+ CD25+bright cells were significantly 
increased in bronchoalveolar lavage fluid in smo-
kers with normal lung function compared with 
people who had never smoked and patients with 
moderate COPD in one study [9], whereas bron-
choalveolar lavage CD4+ CD25+bright cells were 
increased in smokers and patients with COPD 
compared with healthy people who had never 
smoked in another study [8]. The data suggest 
that cigarette smoking exerts influence on the 
pulmonary immune system and can affect the 
development of COPD. The lowest Treg frequency 
was observed not in severe COPD but in healthy 
smokers. This suggests that perhaps the best in-
terpretation is that smoking induces CD25 (either 
induction of Treg or activation of T cells). Accor-
ding to our results, we speculate that the amount 
of Treg in healthy smokers, compared to non-smo-
kers, increases to protect against harmful effects 
of smoking on their lungs. Whereas the immune 
response of these individuals is appropriate, they 
do not develop COPD. On the other hand, for the 
group of COPD patients, we can assume that mild/ 
/moderate COPD is diagnosed in the subjects who 
have more lung-protecting Tregs. Accordingly, 
severe COPD affects those with less Tregs.
D’Alessio and coworkers showed that Tregs 
can play a protective role against lung injuries: 
Tregs that are CD4+, CD25+, and FOXP3+ 
resolve experimental lung injury in mice after 
intratracheal lipopolysaccharide administration 
and are present in the bronchoalveolar lavage 
fluid of patients with acute lung injury, suggesting 
that Treg cells modify innate immune responses 
during resolution of lung injury [19].
A possible role of CD4+ CD25+ bright T- cells in 
COPD pathogenesis was suggested in recent study 
of Chiappori et al. [20], where CD4 + CD25 bright 
CD127- regulatory T-cells percentage was significan-
tly reduced in COPD patients, both current and for-
mer smokers, with respect to volunteers. However, 
in this study, COPD patients were not categorized 
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according to the severity of the disease, except 
according to current or previous smoking history.
Our data are in agreement with another study 
[21], which revealed that in peripheral blood, 
increased proportions of resting Tregs, activated 
Tregs and cytokine-secreting Treg cells with 
proinflammatory capacity were found in smokers 
compared with never-smokers, whereas patients 
with COPD showed decreased resting Tregs, ac-
tivated Tregs and significantly increased pro-in-
flammatory Treg cells compared with smokers.
There is a debate over Treg numbers in COPD 
tissue. According to other studies, the number 
of CD4+ CD25+ FOXP3 Tregs in the bronchial 
biopsies [22] or lungs [23, 24] of patients with 
stable COPD is not significantly different com-
pared with healthy controls but is decreased in 
the small airways of COPD patients, and this 
negatively correlates with the degree of airflow 
obstruction [11, 25]. However, in our study we 
found significantly lower numbers of intraepithe-
lial CD4+ CD25+ lymphocytes in the severe/very 
severe COPD (GOLD III–IV) group as well as in 
the control non-smokers group, compared with 
mild/moderate COPD and control smokers groups. 
The mentioned authors [11, 23, 25] conducted 
research on lung tissue from patients undergoing 
surgical resection for carcinoma and results can 
be influenced by neoplastic process.
Our data was not affected by cancer, because 
neither our COPD patients nor the controls had 
an oncological disease.
In summary, higher Treg frequencies are 
consistent with a protective role of these cells. 
But equally, it could be that more severe disease 
leads to loss of Treg. Normal balance of Treg cells 
in bronchial mucosa and in peripheral blood 
is disturbed in patients with COPD. Patients 
with mild/moderate COPD and healthy smokers 
exhibit higher quantity of Tregs, while patients 
with severe/very severe COPD and healthy non-
smokers exhibit significantly lower quantity of 
Tregs. This suggests that severe COPD develops 
in patients with lower levels of Tregs in the blo-
od and respiratory tract, while a higher Tregs 
concentration in smokers without COPD indi-
cates a potential Treg protective effect against 
developing COPD. 
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